peptide agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-08-08. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
He responded, "Not even a little bit. The only thing that matters when I’m talking about Iran — they can't have a nuclear weapon. I don’t think about Americans’ financial situation. I don't think about anybody. I think about one thing — we cannot let Iran have a nuclear weapon. That's all." He later told Fox News in an interview regarding his previous statement, "That's a perfect statement. I'd make it again." On 25 May, Trump said that any peace agreement with Iran must be tied to the Abraham Accords, stating that it "should be mandatory" for Saudi Arabia, Qatar, and Pakistan to establish diplomatic ties with Israel, in addition to Egypt, Jordan, and Turkey, which already have ties with Israel. On 1 June, following the shutdown of further talks by Iran due to planned Israeli attacks on Beirut, he told CNBC that he did not care and claimed that the negotiation process "started to get very boring". Later the same day, he claimed to have a "very productive call" with Netanyahu and Hezbollah to pause attacks on each other and reenable US talks with Iran.
=== Books === Boitano, Scott; Brooks, Heddwen L.; Barman, Susan M.; Barrett, Kim E. (2016). Ganong's Review of Medical Physiology. McGraw-Hill Education. ISBN 978-0-07-182510-8. Susan Standring, ed. (2008). Gray's anatomy: the anatomical basis of clinical practice (40th ed.). London: Churchill Livingstone. ISBN 978-0-8089-2371-8. Cole, Laurence A.; Kramer, Peter R. (2016). Human Physiology, Biochemistry and Basic Medicine. Amsterdam: Academic Press. ISBN 978-0-12-803699-0.
The "Cave with the Ring-Bearing Doves" (Cave 123) had a type of "central pillar" structure, with niche and circumambulating corridor, but with a very uncharacteristic cubic main cella crowned by a magnificent dome decorated with divinities. The main cella forms a square vestibule or main hall (3.42 x 3.42 meters; 12 x 12 feet) in front of the pillar forming the back wall, the vestibule being surmounted by a decorated dome. The prototype for the dome decorated with standing Buddhist deities is to be found in Group C of the caves at Bamiyan. It can also be seen in some other caves in the region, such as in Kumtura. The cave is named after a pattern of "flying geese holding a wreath" (or ring). This pattern is also known from Cave 69, which is dated to 625–647 CE because of the depiction and inscription of a historically identified king. Because of this marker, Cave 123 may be dated to the same period. Two monumental Buddha images occupy the sides of the main cella. They have full-body "mandorla" halos filled with a multitude of sitting or standing Buddhas. These monumental images represent the second Great Miracle of the Sakyamuni Buddha at Shravasti. The myriads of Buddhas emanating from him, each standing on a lotus, are a result of his deep meditation at Shravasti, as recounted in the Divyavadana. This understanding of the Great Miracle is most prominent among the Sarvastivadin and the Mulasarvastivadin. The two monumental Buddhas are surrounded by attendants, some light-skinned and some dark-skinned, and a Vajrapani.
2-Aminoisobutyric acid is not one of the proteinogenic amino acids and is rather rare in nature (cf. non-proteinogenic amino acids). In the context of cell-free protein synthesis 2-aminoisobutyric acid is compatible with ribosomal elongation of peptide synthesis. Flexizymes and an engineered tRNA body enhance the affinity of aminoacylated Aib-tRNA species to elongation factor P. The result was an increased incorporation of Aib into peptides in a cell free translation system. Iqbal et al.. used an alternative approach of creating an editing deficient valine—tRNA ligase to synthesize aminoacylated Aib-tRNAVal. The aminoacylated tRNA was subsequently used in a cell-free translation system to yield Aib-containing peptides. Aib has been found in meteorites and some antibiotics of fungal origin, such as alamethicin and some lantibiotics.
=== Afghan War === The Canadian Uranium Medical Research Centre obtained urine samples from bombed civilian areas in Jalalabad that showed concentrations of 80 to 400 nanograms per litre (5.6×10−6 to 2.81×10−5 gr/imp gal) of undepleted uranium, far higher than the typical concentration in the British population of ≈5 nanograms per litre (3.5×10−7 gr/imp gal).
Sources: en.wikipedia.org
Computing the total disintegration energy given by the equation Edi = (mi - mf - mp)c2 where mi is the initial mass of the nucleus, mf is the mass of the nucleus after particle emission, and mp is the mass of the emitted (alpha-)particle, one finds that in certain cases it is positive and so alpha particle emission is possible, whereas other decay modes would require energy to be added. For example, performing the calculation for uranium-232 shows that alpha particle emission releases 5.4 MeV of energy, while a single proton emission would require 6.1 MeV. Most of the disintegration energy becomes the kinetic energy of the alpha particle, although to fulfill conservation of momentum, part of the energy goes to the recoil of the nucleus itself (see atomic recoil). However, since the mass numbers of most alpha-emitting radioisotopes exceed 210, far greater than the mass number of the alpha particle (4), the fraction of the energy going to the recoil of the nucleus is generally quite small, less than 2%. Nevertheless, the recoil energy (on the scale of keV) is still much larger than the strength of chemical bonds (on the scale of eV), so the daughter nuclide will break away from the chemical environment the parent was in. The energies and ratios of the alpha particles can be used to identify the radioactive parent via alpha spectrometry. These disintegration energies, however, are substantially smaller than the repulsive potential barrier created by the interplay between the strong nuclear and the electromagnetic force, which prevents the alpha particle from escaping.
A central Food Production Committee, set up in early 1942, organised the conscripted labourers and attempted to help the white farmers to grow all the crops they could. Maize production grew by 40% between 1942 and 1944, the potato harvest doubled and the onion crop grew sixfold by the end of the war. Production of the colony's most important cash crop, tobacco, was high throughout the war, averaging about 40 million pounds (18 million kg) annually. The number of cattle slaughtered by the beef industry increased by 134%, from 71,000 head in 1937 to 160,000 head in 1945. Vegetable dehydration, one of the Food Production Committee's main initiatives, proved a great success, allowing Rhodesia to export many products to the UK that would previously have spoiled in transit. Southern Rhodesia also provided goods to the Eastern Group Supply Council, a body set up in 1940 to co-ordinate the build-up of war materiel in India and other British colonies and dominions east of Suez, with the goal of reducing the amount of supplies shipped from the UK. A Rhodesian officer, Brigadier E G Cook, was the group's deputy controller general. Between 1941 and 1945 Southern Rhodesia contributed large quantities of timber, leather goods, soap and building materials.
== Treatments == Although research is ongoing, treatment options are currently limited; vitamins are frequently prescribed, though the evidence for their effectiveness is limited. Pyruvate has been proposed in 2007 as a treatment option. N-acetyl cysteine reverses many models of mitochondrial dysfunction.
a methyl-cytosine-binding domain (MBD) composed of 85 amino acids; and a transcriptional repression domain (TRD) composed of 104 amino acids The MBD domain forms a wedge and attaches to the methylated CpG sites on the DNA strands. The TRD region then reacts with SIN3A to recruit histone deacetylases (HDAC). There are also unusual, repetitive sequences found at the carboxyl terminus. This region is closely related to the fork head family, at the amino acid level.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
Mass spectrometry provides the most direct confirmation of molecular mass. Reversed-phase chromatography adds a retention-time signature that supports identity when compared against a reference standard. No single method is sufficient on its own.